The diagnosis of obstetric cholestasis (OC) has serious implications for maternal, and especially fetal, health. Total serum bile acid concentration is an important investigation in any woman with itching in the absence of a rash during pregnancy. Results should be available within 1--2 working days. Pruritus plus raised total bile acids in the third trimester suggests a diagnosis of OC. Other biochemical abnormalities, usually a raised alanine aminotransferase, accompany or follow the nding of raised bile acids. Bile acids are sensitive, but not speci c, markers for OC. The diagnosis is one of exclusion. The clinician should remain alert to other causes of liver dysfunction, either speci c to pregnancy or not. Effective treatment is available that improves maternal biochemical indices and well-being. It is not clear whether such treatment reduces the risks to the fetus. More active management of OC pregnancies has reduced the associated fetal and perinatal mortality.
Introduction
The structure of the bile acids, the major constituents of bile, has been known since the 1920s. 1 They remain an area of active research, and our knowledge of their biochemistry and physiology is still growing rapidly. This is partly because their biochemistry is complex, with several alternative biosynthetic pathways and many products of bacterial modi¢cation, and partly because the presence of signi¢cant species di¡erences has hampered the interpretation of research in animal models. Recently improved methods of studying membrane dynamics and DNA analysis have improved our understanding of the events at the hepatocyte canalicular membrane that underlie several cholestatic conditions, with some unexpected therapeutic bene¢ts, and the major role of bile acids in cholesterol homeostasis maintains this interest. Figure 1 shows the structure of the major human bile acids. The steroid nucleus is reduced at C-5, with the hydrogen in the b con¢guration [although small amounts of their allo (5a) isomers are detectable]. This is an important characteristic of the bile acids since it puts the A ring into the cis con¢guration, almost perpendicular to the steroid plane. In human beings the primary bile acids are all a-hydroxylated, bringing all the polar hydrophilic groups to one side of the molecule and giving them characteristic surfaceactive properties.
Bile acids
The primary bile acids synthesized in the human liver are cholic acid [3a,7a,12a-trihydroxy-5b-cholanoic acid (CA)] predominantly, and chenodeoxycholic acid [3a,7a-dihydroxy-5b-cholanoic acid (CDCA)]. These are mostly found as N-aminoacyl conjugates (see below).
The secondary bile acids are derived from bacterial modi¢cation in the terminal ileum and colon, mostly by de-conjugation and 7a-dehydroxylation to deoxycholic acid [3a,12a-dihydroxy-5b-cholanoic acid (DCA)] and lithocholic acid [3a-monohydroxy-5bcholanoic acid (LCA)].
Ursodeoxycholic acid [3a,7b-dihydroxy-5b-cholanoic acid (UDCA)] is detectable only in trace amounts in human subjects. It is probably derived in man from combined gastrointestinal microbial modi¢cation followed by hepatic metabolism, 2 and is therefore sometimes referred to as a tertiary bile acid.
The bile acids are ionized at physiological (and bile) pH, and thus exist as charged bile salts, to which membranes are impervious.
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The situation is more complex in liver disease, when unusual metabolic by-products and intermediates may also be detectable in blood and urine.
Physiology
The biosynthesis and physiology of bile acids has recently been reviewed. 1, 3 The regulatory roles played by bile acids in several metabolic functions and the role played by the liver FXR nuclear receptor (farnesoid X receptor, so named when it was still an orphan receptor, but now recognized as a bile acid receptor) in the close interplay between bile acids and cholesterol homeostasis have been recognized only recently. 4^6 
Canalicular secretion and formation of bile

Bile salt uptake
Bile salts are taken up into the hepatocytes from the liver sinusoids by at least two energy-dependent speci¢c protein transporters:
. Sodium taurocholate co-transporting polypeptide (NTCP), which is dependent on the transmembrane sodium gradient and is relatively speci¢c for conjugated and unconjugated bile salts, and some other conjugated sterols. 7 It is responsible for about 95% of bile acid transport. Its expression is regulated by bile acid concentrations. 8 . Organic anion transporting polypeptide 1 (OATP1), and OATP2, which are sodium-independent and have a much broader speci¢city, transporting bile salts, conjugated steroids such as 17b-oestradiol glucuronide, organic anions (including conjugated bilirubin) and thyroid hormones.
Bile salt secretion
Up to 30 g/day of bile salts are secreted across the hepatocyte canalicular membrane, 9 requiring energydependent, co-ordinated transport mechanisms. This is a rate-limiting process and it is hardly surprising that the canalicular membrane is the likely site of many causes of intrahepatic cholestasis. Studies of inherited cholestatic conditions that may be allelic to obstetric cholestasis [progressive familial intrahepatic cholestasis (PFIC) and the related benign recurrent intrahepatic cholestasis (BRIC) 10 ] have led to the identi¢cation of a number of transport proteins (some belonging to the ATP-binding cassette family) that are involved in this process: 11 . The canalicular secretion of bile salts is mediated predominantly by the bile salt export pump (BSEP). 12 This ATP-dependent bile salt transporter (which has previously been called BAT, and sister of P-glycoprotein or SPGP) is relatively speci¢c for bile salts and is expressed only in the liver. It is de¢cient in PFIC2 kindreds, the gene mapping to chromosome 2q24. 13 . Kindreds with the severe cholestatic phenotype PFIC1, and also the more benign BRIC, have mutations in the FIC1 gene, which maps to chromosome 18q21^22. 14 This gene codes for a P-type ATPase, which mediates out-to-in transmembrane transfer of phosphatidylserine and phosphatidylethanolamine. 15 The physiological role of this protein in bile salt secretion in not yet understood. . The multidrug resistance gene product MDR3 (confusingly called mdr2 in the mouse model), encoded on chromosome 7q21, is mutated in some kindreds with inherited cholestasis. 16 This phenotype also usually has an elevated serum g-glutamyltransferase (g-GT) and has been called PFIC3. The product appears to be a`£ippase', enabling the movement of phosphatidylcholine (the other major constituent of mixed micelles) from the inner to the outer lea£et of the plasma membrane. 10 This is presumably necessary for the formation of the initial mixed bile salt^phosphatidylcholine vesicles.
Another multiresistance-associated transport protein, MRP2, has broad speci¢city (and has also been called multispeci¢c organic anion transporter) and transports many organic anions, including conjugated bile salts. It may be of particular importance in cholestatic conditions when other bile salt transport processes have failed. 8
Enterohepatic circulation
The normal dynamics of bile acid circulation are summarized in Table 1 (data represent typical values compiled from the literature).
The result of e¤cient ¢rst-pass hepatic extraction is that bile acids are present only at very low concentrations in the systemic circulation. In the normal fasting state, concentrations of total 3a-hydroxy bile acid (de¢ned enzymatically, see below) are typically around 3^5 mmol/L, or even less when measured by gas chromatography^mass spectrometry (GC^MS). CDCA predominates. CA, LCA and DCA are typically each present at about half the concentration of CDCA, although CA may become the dominant species in cholestatic conditions. All bile salts can be conjugated. LCA is almost all conjugated, but other unconjugated bile salts may constitute 30^40% of the total. 17 Glycine conjugates are present at about twice the concentration of the taurine conjugates, but the latter are dependent on dietary taurine (and are therefore much lower in the newborn). Sulphate conjugates form about 11% of the total; LCA (the most hydrophobic and therefore most cytotoxic bile acid) exists Serum bile salts are 60^85% protein-bound, mostly to albumin and also signi¢cantly to high-density lipoprotein particles. 18 Fasting serum bile acid concentrations £uctuate slightly through intrinsic gastointestinal activity, and there is a small diurnal variation. 17 Serum total bile acid concentrations increase 2^5-fold after meals, peak at 60^90 min, and return to fasting levels over a period of hours. These physiological changes become less signi¢cant when bile acid levels are pathologically elevated.
Measuring bile acids
A full and thorough review of the methods available for measuring bile acids in biological £uids has been published recently 19 and we do not intend to repeat this work. For individual bile acid measurements, GC^MS is probably the best technique for a reference method. More recently, fast atom bombardment MS (FAB-MS) and tandem MS methods have been described. 20 Total bile acids in serum are easily and conveniently estimated by enzymatic^spectrophotometric assay. 19 These assays are usually based on microbial 3ahydroxysteroid dehydrogenase. Other serum dehydrogenases, particularly lactate dehydrogenase, may contribute to the apparent production of NADH and so are inhibited by the addition of, for example, pyruvate or oxamic acid. 21 Commercial kits are available. Other systems are based on 7a-hydroxysteroid dehydrogenase and 12a-hydroxysteroid dehydrogenase. The enzymes used have high speci¢city, showing almost no activity towards 3-ketosteroids or 3b-hydroxysteroids; any other 3a-hydroxysteroid species are thought to be present only at very low concentrations, and are mostly 3O-sulphoconjugated. 22 The method does not work well with heparinized plasma because of high background absorbance. Protein binding can also a¡ect the absorbance, so the method must be calibrated against standards made up in a serum matrix. 22 The most important limitation of enzymatic methods is low sensitivity, the lowest concentration of total serum bile acids measurable being around 1¢5 mmol/ L. A bioluminescence adaptation has been developed which has increased sensitivity down to the picomolar level, 23 but has not been widely exploited. Thus, the standard enzymatic assays struggle to measure variations in total bile acids around normal physiological concentrations, but they are easily capable of measuring pathological elevations.
Clinical usefulness of bile acid estimation
The main determinants of systemic venous concentrations of total bile acids are absorption from the gut (in turn dependent upon bile canalicular secretion) and hepatic extraction. The usefulness of total bile acid measurements in serum is still debated: some feel they o¡er no advantage over existing tests for liver disease, 24 whereas others consider they o¡er greater sensitivity and speci¢city over alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and alkaline phosphatase (ALP) in a variety of conditions a¡ecting the liver. 19, 25 They may have a role in the monitoring of compensated cirrhosis when other standard`liver function' tests are within normal limits but serum bile acid concentrations may be elevated because of portosystemic shunting, 26 or in Gilbert's syndrome when fasting serum bile acids remain normal. 27 The major indication for serum total bile acid measurement, however, is in the di¡erential diagnosis of itching in pregnancy.
Obstetric cholestasis
Obstetric cholestasis (OC) (or intrahepatic cholestasis of pregnancy) occurs almost always in the third trimester of pregnancy. The condition is associated with a signi¢cant perinatal mortality and maternal morbidity.
Incidence and epidemiology
The prevalence of OC varies throughout the world. The highest rates have been found in Bolivia (9%) 28 and in Chile (with rates of 12^22% in certain ethnic groups). 29 In Scandinavia, reported rates are 1 ¢ 52 %, 30 whereas elsewhere in Europe rates are lower, such as in France (0¢2^0¢5%). 31 The prevalence in the UK has not been rigorously established, but has been estimated at about 0¢6% in the white population. 32 There are reported variations with race, the incidence being higher in native South Americans, 33 and with the season, being higher in the winter months. 30 Overall, the incidence appears to be increasing, although this may be a result of increased awareness of the condition.
Aetiology and pathogenesis
The aetiology of OC remains obscure. It is likely to be multifactorial, with a genetic element contributing to an unusual sensitivity to hormonal or environmental factors. Oestrogen seems to be the most important immediate precipitant: the condition is almost exclusive to the third trimester of pregnancy when oestrogen levels are highest. Some women may develop similar symptoms when taking the combined oral contraceptive pill 34 or when challenged with oestrogens, 35 or occasionally at certain times of the menstrual cycle. 36 Some groups have suggested that progesterone may also play a role. 31 Environmental in£uences upon the condition are suggested by the geographical and seasonal variability mentioned above, but the factors involved are so far purely speculative. An association with low dietary selenium intake has been demonstrated. 37 There are marked ethnic variations in the prevalence of OC. In addition, up to 30^50% of women with OC report a positive family history. 36, 38 A genetic predisposition therefore seems likely, and the study of some kindreds has suggested a mendelian dominant pattern of inheritance. 39 The pathogenesis of OC remains a mystery. The predominant biochemical ¢nding is elevation of total serum bile acids. It is highly likely that there is a defect in the hepatocellular excretion of bile acids; a decrease in hepatic clearance of bromsulphthalein has been demonstrated in subjects with a family history of the condition when challenged with ethinyl oestradiol. 40 Histology of liver biopsies shows only centrilobular bile staining and bile plugs in the canaliculi, with no evidence of in£ammatory in¢ltrate or hepatocellular necrosis. 41 Studies of PFIC and BRIC suggest several possible transport mechanisms that may be at fault. The genes encoding these transport proteins, described above, are obvious candidate genes and are currently the subject of much research. Indeed a dysfunctional missense mutation has recently been described in the MDR3 gene in a patient with OC with raised g-GT. 42 How defects in these genes might encode an oestrogen-sensitive defect in transmembrane bile acid secretion remains an enigma.
Clinical features and presentation
The cardinal feature of OC is generalized prutitis. This usually starts in the third trimester (although presentation even in the ¢rst trimester has been described), increases as the pregnancy progresses and wanes rapidly after delivery. 33 The itching typically starts on the soles of the feet and palms of the hands and then spreads. It is usually severe, often worse at night, and may prevent adequate sleep. By de¢nition there is no skin rash, although excoriations may be seen due to excessive scratching.
There may occasionally be signs of obstructive jaundice which, if present, usually follows the onset of pruritus, and in contrast tends to plateau rather than increase throughout pregnancy. 43 Systemic symptoms such as malaise and anorexia, if present, are usually mild. There are no other physical signs.
Although some women may experience one or more una¡ected pregnancies prior to developing OC, the recurrence in subsequent pregnancies then approaches 90^100%.
Effects on fetus and mother
The e¡ects of OC on the mother are debilitating, but transient; the e¡ects on the fetus, however, can be catastrophic. In the mother, the disruption of normal bile salt function may impair vitamin K absorption, and there appears to be an increased risk of postpartum haemorrhage. 44 The fetus in a¡ected pregnancies appears to be at greater risk of several adverse events:
. Intrauterine death and perinatal death. Mortality rates seem to be improving with active treatment: in one series rates fell from 107/1000 over the period 1965^1974 to 35/1000 in 1975^1984. 45 Deaths usually occur after 36 weeks, and with little or no warning. . Intrapartum events. Fetal distress occurs in 122 2%, and meconium staining of the amniotic £uid in 25^45%. 45 . Spontaneous pre-term delivery, in 12^44% of a¡ected pregnancies. 43, 45 . Increased rates of intracranial haemorrhage. 46 Recent data from a UK cohort of 81 cases (recruited from a patient support group) have con¢rmed stillbirth in 17%, pre-term birth (spontaneous and iatrogenic) in 37% and fetal distress in 15%. 36 
Diagnosis
Signs and symptoms
There is no single diagnostic clinical sign or test for OC. Information about previous pregnancies, similar symptoms while taking the oral contraceptive pill or in other family members may support the diagnosis, but a diagnosis of OC is one of exclusion. Therefore a careful history should seek out risks for any preexisting liver disease, alcohol consumption, other drug use, or risk factors for viral hepatitis.
An abdominal ultrasound scan should be arranged to exclude post-hepatic causes of cholestasis; a ¢nding of hepato/splenomegaly would suggest an alternative diagnosis.
Biochemical tests
Measurement of serum bile acids has been shown to be the most sensitive test for detecting OC. Total bile acids are elevated, up to 100 times normal. On the few occasions when this has been studied prospectively, the rise in bile acids may precede the onset of symptoms by several days (e.g. in four out of eight women with OC), 47 but generally the rise in bile acids coincides with the onset of symptoms 48 or occurs soon after. 49 In una¡ected pregnancies the concentrations of bile acids change little. 50 In OC pregnancies the rise is earlier and greater in CA than in CDCA, reversing the normal CA/CDCA ratio of 51. 50 DCA increases only moderately, and may decline after a few weeks, as would be expected. The total circulating bile acids will £uctuate somewhat as the pregnancy progresses, but overall there is an inexorable rise towards term. Mean CA concentrations in a series of 45 a¡ected pregnancies were 20 times the upper limit of normal. 47 This is far greater than the normal diurnal and post-prandial variations described above. Fasting samples are therefore not necessary, and most centres will quote a slightly higher reference value that is appropriate for random normal samples. Any elevation above this limit should therefore be regarded as suspicious.
Liver enzyme activities are often abnormal in OC: ALT and AST are usually elevated. The rise is more modest than that of bile acids, typically to 2^3 times normal levels. It is important to compare the enzyme activities with reference values that are speci¢c to pregnancy. 51 ALT seems to be the more sensitive transaminase; 50 the rise often follows the increase in bile acids and may represent hepatocellular damage as a consequence of cholestasis.
The relative sensitivities of these tests for detecting OC has been confused by inconsistent de¢nitions of the condition. Most of the studies measured speci¢c bile acid classes by radioimmunoas say or GC. Laatikainen and Ikonen 48 in 1977 de ned OC as the presence of raised transaminases plus symptoms, and found elevated bile acids in 92% of cases. Heikkinen et al. 47 in 1981, again de¢ning the condition in terms of a raised transaminase plus symptoms, found elevations of bile acids in 100% of cases, but they also describe nine of 49 control' women with itching and normal ALT values who had elevated circulating bile acids. This group, studying 45 OC pregnancies (eight of them prospectively), found that, at the time of the ¢rst elevated bile acid result, the ALT was elevated in 50% of women, AST in 12¢5% and g-GT in 37%. During subsequent followup, the serum CAwas elevated more often than ALT (in 71% and 65% of samples, respectively), but noted that abnormally high levels of either CA or ALT were found at least once in every woman with OC.
A prospective study of 297 unselected pregnancies in Australia 52 concluded that raised serum bile acids (cholylglycine) plus pruritus was the best indicator of OC, and found elevations of transaminases in about half these cases. They also suggested that a larger population (5%) might exist with`subclinical' or biochemical' cholestasis (i.e. raised bile acid concentrations but no symptoms). There has been no other work to con¢rm this ¢nding.
A more recent, smaller longitudinal study of pregnancies a¡ected by OC showed that the onset of pruritus may precede the ¢rst biochemical abnormality by several weeks, so that repeat testing in cases of high clinical suspicion is justi¢ed. 49 Interestingly, this study also showed that increased serum total bile acids was more often the ¢rst biochemical abnormality than an elevated ALT activity (AP Kenyon, personal communication).
ALP activity, mainly the placental isoenzyme, is increased in the third trimester of pregnancy. The normal range is so wide that ALP measurement contributes little to the diagnosis of OC. Serum bilirubin concentration may be modestly increased in up to 30% of cases 50 (and may be detected in the urine by stix testing), but this and other tests of liver function do not contribute to diagnosis or management. g-GT may be elevated in about a third of cases. 50 In the absence of any`gold standard'de¢nition of the disease, most clinicians take the pragmatic approach and consider the diagnosis in any woman presenting with typical symptoms and at least one biochemical liver abnormality, be that elevation of total bile acids, transaminase or g-GT activity, having excluded other causes.
Since bile acids are the most sensitive marker for OC, and pruritus may precede abnormalities in transaminases, total bile acid concentration is an important investigation which may alter management if OC is con¢rmed. Itching is common in pregnancy and, while other causes of itching may be treated conservatively, in OC planned early delivery is likely to be required because of the risk to the fetus. Serum bile acid results should be available within 1^2 working days.
Other causes of hepatic dysfunction must be excluded, and further investigation should therefore include viral serology (including hepatitis C, EpsteinB arr virus and cytomegalovirus) and anti-smoothmuscle and anti-mitochondrial autoantibodies. Full blood count, plasma or serum urate concentration and urinary protein excretion should be measured, and an ultrasound scan of the liver should be undertaken to exclude pre-eclampsia, HELLP syndrome (haemolysis, elevated liver enzymes and low platelets) and acute fatty liver of pregnancy. Renal function, plasma urate and glucose concentrations remain normal in OC, unlike the other conditions.
It is a diagnostic requirement that all biochemical abnormalities and symptoms disappear after delivery. Prolonged persistence of the clinical features of OC, up to 43 weeks post partum, has been described, 43 but persistence for more than a few weeks should generally provoke a search for alternative diagnoses.
Management of OC
Clinical monitoring of blood pressure, urinary protein and renal function should continue during follow-up, and the diagnosis should be reviewed at intervals, because other pregnancy-related hepatic disorders may develop or become manifest. 33 Bile acid concentrations may be monitored to support the diagnosis, but the levels have little prognostic information. Attempts to correlate fetal outcome with maternal bile acid concentrations and disease severity have been inconsistent and unconvincing. 43, 44, 53 The traditional liver function tests, especially ALT, should be monitored at least weekly, although there is no relationship between transaminase levels and either maternal symptoms or fetal distress. The prothrombin time should be measured at least weekly towards term. 43 The mainstay of management of OC is early delivery, and this is usually planned for 37^38 weeks. Close fetal monitoring during induction and labour is imperative.
Fetal surveillance
There is still much debate about the value of fetal monitoring. The prediction of fetal compromise is di¤cult: growth and development are usually normal for gestational age, and cardiotocographic recordings usually show no abnormality. Some authors have advocated amniocentesis to detect meconium staining, 45 but this is not widely practised. Weekly estimations of liquor volume and umbilical artery Doppler ultrasound are commonly performed 54 and twice weekly cardiotocography, but even these measures may fail to predict a sudden catastrophic event.
Drug therapy
Oral phytomenadione (vitamin K) should be given from diagnosis, or from 32 weeks, whichever is later.
Symptomatic relief with antihistamines may be ine¡ective, and does not address the underlying pathology.
Cholestyramine has been used to reduce the bile acid load; large doses are required, which are poorly tolerated and probably do not improve fetal or maternal outcome. 55 The use of high-dose cholestyramine may exacerbate a relative vitamin K de¢ciency.
S-Adenosylmethionine (SAM) has been used with some encouraging results in small numbers of patients, 56 but others have not con¢rmed this. 57 Dexamethasone has been tried in small numbers with very encouraging results. 58 Although not yet licensed for this use, UDCA is increasingly the drug of choice in OC. It has been known since the early 1990s to improve both symptoms and liver function tests in the mother. A more detailed study showed an improvement in the bile acid pro¢le on UDCA treatment, with the CA/CDCA ratio decreasing towards normal by a reduction in CA, and the total bile acid glycine/taurine ratio normaliz ing. 59 However, UDCA produced no improvement in the altered bile acid pro¢le in the meconium of the newborn in OC pregnancies. 60 The important question is whether UDCA produces any real improvement in fetal outcome: the only randomized, blinded and placebo-controlled trial of UDCA so far (nˆ15) has suggested a decrease in adverse fetal events. 61 Another small (nˆ32) randomiz ed controlled trial of UDCA versus SAM versus UDCA+SAM versus placebo suggested a greater improvement in maternal indices with the combination of agents. 62 UDCA does not result in clinical or biochemical improvement in all patients.
Future work
Future studies into the cause of raised bile acids in pregnancy will help elucidate the aetiology of cholestasis and of unexplained third-trimester intrauterine death in general. At present, MDR3 is the only gene in which mutations have been found in OC, and these were reported in a subgroup of women with a raised g-GT. 42, 63 Approximately 30% of women with OC have a raised g-GT. 42 Molecular studies of the other bile acid transporters may identify more predisposing mutations.
There have been few studies of the mechanisms of intrauterine death in OC. 64 To increase understanding, a large number of OC pregnancies will need to be studied. This is not feasible for a single unit. A recent initiative is the establishment of a web-based international registry of all OC-related intrauterine deaths. This is called IRIS (International Registry of Intrahepatic Cholestasis of Pregnancy-related Stillbirths) and can be accessed via the web address http://escuela.med.puc.cl/iris/welcome.html. This will allow the prospective collection of information from pregnancies complicated by intrauterine death. As we learn more about the aetiology of OC, it will be of interest to investigate the role of raised bile acids in the pathophysiology of other liver disorders of pregnancy.
